Evidence map›Paper›PMID 25912534›Full record

ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2015

N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review.

Georgina Oliver, Olivia Dean, David Camfield, Scott Blair-West, Chee Ng, Michael Berk, Jerome Sarris

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Georgina OliverDepartment of Psychiatry, The Melbourne Clinic, The University of Melbourne, Melbourne, Australia.
Olivia DeanDepartment of Psychiatry, The Melbourne Clinic, The University of Melbourne, Melbourne, Australia.
David CamfieldCentre for Human Psychopharmacology, Swinburne University, Melbourne, Australia.
Scott Blair-WestDepartment of Psychiatry, The Melbourne Clinic, The University of Melbourne, Melbourne, Australia.
Chee NgDepartment of Psychiatry, The Melbourne Clinic, The University of Melbourne, Melbourne, Australia.
Michael BerkDepartment of Psychiatry, The Melbourne Clinic, The University of Melbourne, Melbourne, Australia.
Jerome SarrisDepartment of Psychiatry, The Melbourne Clinic, The University of Melbourne, Melbourne, Australia.
Melbourne Clinic · AUUniversity of Melbourne · AUDeakin University · AUSwinburne University of Technology · AUUniversity of Wollongong · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveObsessive compulsive and related disorders are a collection of debilitating psychiatric disorders in which the role of glutamate dysfunction in the underpinning neurobiology is becoming well established. N-acetyl cysteine (NAC) is a glutamate modulator with promising therapeutic effect. This paper presents a systematic review of clinical trials and case reports exploring the use of NAC for these disorders. A further objective was to detail the methodology of current clinical trials being conducted in the area.

methodsPubMed, Web of Science and Cochrane Library Database were searched for human clinical trials or case reports investigating NAC in the treatment of obsessive compulsive disorder (OCD) or obsessive compulsive related disorders. Researchers with known involvement in NAC studies were contacted for any unpublished data.

resultsFour clinical trials and five case reports/series were identified. Study durations were commonly 12-weeks, using 2,400-3,000 mg/day of NAC. Overall, NAC demonstrates activity in reducing the severity of symptoms, with a good tolerability profile and minimal adverse effects. Currently there are three ongoing randomized controlled trials using NAC for OCD (two adults and one pediatric), and one for excoriation.

conclusionsEncouraging results have been demonstrated from the few pilot studies that have been conducted. These results are detailed, in addition to a discussion of future potential research.

Indexed as

acetylcysteineGlutamateObsessive-compulsive disorderReviewsystematicTrichotillomania

Identifiers

PMID25912534
PMCPMC4423164
OpenAlexW1992261726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.